Investment Thesis
Compass Therapeutics is a pre-revenue biotech company with negative profitability and substantial cash burn ($17.3M operating; $17.4M free cash flow annually). While the balance sheet is strong with $55.2M cash and zero debt, the lack of revenue generation and persistent operating losses (-$20.3M) indicate the company has not achieved commercial viability. At current burn rates, cash runway extends approximately 3+ years, but the path to profitability remains uncertain without demonstrated revenue.
Strengths
- Strong balance sheet with $186.5M stockholders' equity and minimal liabilities ($18.7M)
- Substantial cash position of $55.2M with no long-term debt, providing financial flexibility
- Excellent liquidity ratios (current ratio 19.04x) enabling operational flexibility during development phase
Risks
- Zero revenue with complete loss of prior-year revenue (-100% YoY), indicating failed or absent commercialization
- Significant operating cash burn of $17.3M annually against limited revenue generation capacity
- High execution risk inherent in biotech sector; company remains pre-commercial with unproven pipeline value
Key Metrics to Watch
- Quarterly revenue generation and time to first commercial milestone
- Operating cash burn rate and remaining cash runway
- Progress on clinical trials and regulatory approvals for pipeline candidates
Financial Metrics
Revenue
0.0
Net Income
-18.3M
EPS (Diluted)
$0.00
Free Cash Flow
-17.4M
Total Assets
205.2M
Cash
55.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-9.8%
ROA
-8.9%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
19.04x
Quick Ratio
19.04x
Debt/Equity
0.00x
Debt/Assets
9.1%
Interest Coverage
N/A
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T08:52:05.817951 |
Data as of: 2026-03-31 |
Powered by Claude AI